• LAST PRICE
    1.6882
  • TODAY'S CHANGE (%)
    Trending Down-0.0118 (-0.6941%)
  • Bid / Lots
    1.6800/ 20
  • Ask / Lots
    1.7000/ 10
  • Open / Previous Close
    1.7400 / 1.7000
  • Day Range
    Low 1.6600
    High 1.7400
  • 52 Week Range
    Low 0.5200
    High 3.3500
  • Volume
    23,314
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 1.7
TimeVolumeENTX
09:32 ET43181.66
09:37 ET3751.74
09:42 ET1001.7
09:50 ET10001.7207
10:15 ET5001.7
10:18 ET1001.71
10:27 ET1001.7
10:40 ET16251.68
10:51 ET10001.68
11:18 ET1001.68
11:38 ET2001.68
11:48 ET2001.68
12:03 ET50001.7229
12:06 ET1001.68
12:15 ET1001.71
12:44 ET3601.715
12:50 ET2501.7
01:00 ET1001.68
01:08 ET1001.68
01:11 ET50001.71
01:18 ET2861.6875
01:22 ET1001.73
01:27 ET1001.6801
01:36 ET1001.69
02:00 ET10001.6882
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesENTX
Entera Bio Ltd
62.6M
-6.4x
---
United StatesMAIA
Maia Biotechnology Inc
62.9M
-1.6x
---
United StatesRTGN
RetinalGenix Technologies Inc
63.0M
-15.3x
---
United StatesMURA
Mural Oncology PLC
61.7M
-0.3x
---
United StatesNVNO
enVVeno Medical Corp
63.9M
-2.6x
---
United StatesRAPT
RAPT Therapeutics Inc
61.1M
-0.6x
---
As of 2024-11-12

Company Information

Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

Contact Information

Headquarters
Hadassah / Jerusalem Bio Park, 5th FloorJERUSALEM, Israel 9112002
Phone
---
Fax
---

Executives

Independent Chairman of the Board
Gerald Lieberman
Chief Executive Officer, Director
Miranda Toledano
Chief Financial Officer
Dana Yaacov-Garbeli
Chief Operating Officer
Hillel Galitzer
Chief Financial Officer - United States
Ramesh Ratan

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$62.6M
Revenue (TTM)
$57.0K
Shares Outstanding
36.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.57
EPS
$-0.26
Book Value
$0.29
P/E Ratio
-6.4x
Price/Sales (TTM)
1,098.5
Price/Cash Flow (TTM)
---
Operating Margin
-15,045.61%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.